

Journal section: *Implantology*  
Publication Types: *Review*

doi:10.4317/medoral.27721

## Failures and complications associated with resorbable and non-resorbable membranes in guided bone regeneration: A systematic review and meta-analysis

Daniela Sánchez Cousiño <sup>1</sup>, Sonia Egido-Moreno <sup>2</sup>, Beatriz González Navarro <sup>2</sup>, Holmes Ortega Mejía <sup>1</sup>, Andrés Blanco-Carrión <sup>3</sup>, José López-López <sup>4</sup>

<sup>1</sup> Faculty of Medicine and Health Sciences, University of Barcelona, 08907 Barcelona, Cataluña, Spain

<sup>2</sup> Department of Odontostomatology. Faculty of Medicine and Health Sciences (Dentistry), University of Barcelona 08907 Barcelona, Cataluña, Spain

<sup>3</sup> Oral Medicine, Oral Surgery and Implantology Unit (MedOralRes), Faculty of Medicine and Dentistry Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Instituto de Investigación Sanitaria de Santiago (IDIS), ORALRES Group, Santiago de Compostela, Spain

<sup>4</sup> Dental Hospital of the University of Barcelona (HOUB), Department of Odontostomatology. Faculty of Medicine and Health Sciences (Dentistry), University of Barcelona, 08907 Barcelona, Cataluña, Spain

### Correspondence:

Faculty of Medicine and Health Sciences (Dentistry)  
University of Barcelona, Bellvitge University Campus  
Government Pavilion. Office 2-29. C/Feixa Llarga, s/n  
08907, Barcelona, Spain  
18575jll@gmail.com  
soniaegido@ub.edu

Please cite this article in press as: Cousiño DS, Egido-Moreno S, Navarro BG, Mejía HO, Blanco-Carrión A, López-López J. Failures and complications associated with resorbable and non-resorbable membranes in guided bone regeneration: A systematic review and meta-analysis. *Med Oral Patol Oral Cir Bucal*. 2025.  
doi:10.4317/medoral.27721

Received: 13/08/2025  
Accepted: 03/02/2026

Article Number: 27721 <http://www.medicinaoral.com/>  
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946  
eMail: [medicina@medicinaoral.com](mailto:medicina@medicinaoral.com)  
**Indexed in:**  
Science Citation Index Expanded  
Journal Citation Reports  
Index Medicus, MEDLINE, PubMed  
Scopus, Embase and Emcare  
Indice Médico Español

### Abstract

**Background:** Patients treated with guided bone regeneration (GBR) may be treated using resorbable or non-resorbable membranes, which differ in their efficacy, failures and complication profiles.

The objective is to evaluate the efficacy and failures and complications of resorbable membranes versus non-resorbable membranes in patients undergoing guided bone regeneration (GBR). A search was conducted until July 31, 2025. Randomized clinical trials (RCTs) comparing both types of membrane in ROG were the eligibility criteria.

**Material and Methods:** Data collection and risk of bias assessment (RoB 2.0) were performed. Primary endpoints included bone regeneration efficacy and membrane-associated complications.

**Results:** Twenty-five RCTs with a total of 684 patients were included. Most studies reported a high success rate for both types of membranes. However, non-resorbable membranes had a higher incidence of complications, such as membrane exposure (up to 71%), disinheritance and infections.

**Conclusions:** Both types of membranes are effective for ROG, they should be chosen according to the defect and type of patient. Resorbable membranes have a lower complication rate and non-resorbable membranes offer greater dimensional stability and the need to perform a second surgery for its removal.

**Keywords:** *Guided bone regeneration, complications, resorbable membranes, non-resorbable membranes, systematic review.*

## Introduction

Alveolar bone atrophy is a frequent consequence of tooth loss and manifests as progressive bone resorption that can reach moderate or severe degrees. This resorption is due to the absence of the functional stimulus that the teeth exert on the alveolar bone, which triggers a continuous process of bone loss. The speed and pattern of this resorption depends, among other factors, on the anatomical location [1]. To address bone volume loss after extraction, multiple augmentation techniques have been developed, which can be applied to both the maxilla and the mandible, depending on the type and extent of the defect. Among the most used are bone grafts, either in the form of blocks (onlays) or particulate, osteodistraction, guided bone regeneration (GBR), transposition of the inferior alveolar nerve and the use of containment devices such as titanium meshes [1]. In the context of GBR, two main approaches can be used depending on the type of membrane selected: Nonresorbable membranes, such as titanium-reinforced polytetrafluoroethylene (PTFE) membranes, and resorbable membranes, usually collagen. In vertical regeneration procedures, resorbable membranes require additional support to maintain the necessary space for bone formation, such as a titanium mesh or an osteosynthesis plate [1]. However, the use of barrier devices involves a demanding surgical technique and is not without complications. The main cause of failure in GBR procedures is premature or late exposure of the membrane, which can lead to contamination of the biomaterial and irreversibly compromise bone regeneration [1]. Furthermore, in the case of non-resorbable membranes, a second surgical intervention is required for their removal, usually six to eight months after placement [2]. In contrast, resorbable membranes have the advantage of eliminating the need for additional surgery, and present a lower risk of exposure, perforation and infection. However, the choice of membrane type depends on multiple clinical factors, including the size of the defect and the presence or absence of supporting bone walls. For this reason, both non-resorbable membranes and titanium meshes continue to be therapeutic options especially indicated in extensive bone defects or in atrophic ridges lacking walls, although regeneration in these cases tends to be slower [3].

## Material and Methods

The review was prepared according to Cochrane Collaboration guidelines and reported following the PRISMA extension statement for reporting systematic reviews incorporating network meta-analyses of health care interventions (PRISMA-NMA) [4]. The following question was developed: In patients undergoing guided bone regeneration, are resorbable membranes more effective and have fewer failures and complications than non-resorbable membranes?

### *Study eligibility criteria (in PICO format)*

P (Population): Patients undergoing guided bone regeneration (GBR) procedures with the use of membranes. I (Intervention): Use of resorbable membranes for guided bone regeneration. C (Comparison): Use of non-resorbable membranes for guided bone regeneration. O (Outcome - Results). Efficacy: success rate of bone regeneration (e.g., new bone formation, graft stability). Failures: Membrane exposure, graft loss, infections. Clinical complications: Inflammation, undesirable bone resorption, need for reoperation.

### *Inclusion and exclusion criteria*

Inclusion criteria: Population: Patients undergoing guided bone regeneration (GBR) using membranes. Intervention and comparison: Use of resorbable membranes vs. non-resorbable membranes in guided bone regeneration procedures or membranes vs. a control group. Results: Reports results related to: Efficacy: New bone formation, graft stability. Failures: Membrane exposure, infections, graft loss, unwanted bone resorption. iv.-Study design: Randomized controlled trials (RCTs). Clinical studies with comparisons between membrane or control groups. v.-Language: Published in English or Spanish.

Exclusion criteria: Does not compare resorbable and non-resorbable membranes directly or membranes with respect to a control group. Does not report specific results on bone regeneration (efficacy or failures). Animal or *in vitro* studies. Descriptive studies, systematic reviews, case series or studies without a comparative group.

### *Search strategy and information resources*

Electronic searches were conducted until July 31, 2025 in four databases: CENTRAL (Cochrane Central Register of Controlled Trials), OVID MEDLINE, EMBASE and Web of Science. For PubMed, MeSH terms and free terms combined using Boolean operators were used, with the following search strategy: (("Guided Bone Regeneration"[MeSH] OR "Alveolar Ridge Augmentation"[MeSH] OR "Bone Regeneration") AND ("Absorbable Implants"[MeSH] OR "Biodegradable Materials"[MeSH] OR "bioabsorbable membranes" OR "resorbable membranes") AND ("Non-Absorbable Membranes" OR "Polytetrafluoroethylene"[MeSH] OR "non-bioabsorbable membranes" OR "non-resorbable membranes")) AND ("Bone Formation"[MeSH] OR "Bone Regeneration"[MeSH] OR "Treatment Outcome"[MeSH] OR "Postoperative Complications"[MeSH] OR "Treatment Failure"[MeSH]) AND (Humans[MeSH]) AND (english[Language] OR spanish[Language]). For the Cochrane database, the same search strategy was used: (("Guided Bone Regeneration"[MeSH] OR "Alveolar Ridge Augmentation"[MeSH] OR "Bone Regeneration") AND ("Absorbable Implants"[MeSH] OR "Biodegradable Materials"[MeSH] OR "bioabsorbable membranes" OR "resorbable membranes") AND ("Non-Absorbable Membranes" OR "Polytetrafluoroethylene"[MeSH] OR "non-

bioabsorbable membranes" OR "non-resorbable membranes") AND ("Bone Formation"[MeSH] OR "Bone Regeneration"[MeSH] OR "Treatment Outcome"[MeSH] OR "Postoperative Complications"[MeSH] OR "Treatment Failure"[MeSH]).

#### Study selection and data extraction

The selection of titles and abstracts was performed by a reviewer (DSC). In case of doubt, the decision on which articles to review in full text was made by discussion with the review team (SEM). A reviewer (DSC) then reviewed the full text of the articles for inclusion. Again, in case of uncertainty, the decision on inclusion or exclusion was made by discussion with the review team. Data extraction forms were then developed, tested on several articles, and modified if necessary, before use. Next, one reviewer (DSC) extracted the data, and two other reviewers (SEM, JLL) checked a randomly selected sample (50%) of the extracted data. The following data were extracted: Context, study design, population characteristics (no. of patients, types of defects, location), details of interventions, and information on primary and secondary outcomes.

#### Quantitative methods

Pooled analyses were performed using a random-effects model. Study heterogeneity was assessed using the I<sup>2</sup> statistic. Heterogeneity between studies was considered statistically significant for a *p*value < 0.05 and was interpreted according to Cochrane Handbook recommendations: 0%-40% was considered unimportant, 30%-60% as moderate heterogeneity, 50%-90% as substantial heterogeneity, and

75%-100% as considerable heterogeneity. Review Manager 5.4 was used as a tool to analyze the data, previously recorded an Excel table. Forest Plots were made to graphically represent the difference between the different types of membranes, with a 95% confidence interval (CI).

#### Assessment of risk of bias and certainty of evidence

Risk of bias was assessed at the outcome level in all included RCTs using the Cochrane Risk of Bias (RoB) 2.0 tool [5]. Certainty in evidence (CiE) was assessed at the outcome level using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach [6]. Assessment of publication bias using funnel plots was not performed because the number of studies included in each meta-analysis was limited, which precluded a meaningful evaluation.

## Results

### Study selection

A total of 98 records were identified, of which all were electronically searched. After eliminating duplicates, the titles and/or abstracts of 82 records were examined. Once irrelevant titles and abstracts were excluded, the full texts of 37 publications were examined, allowing us to exclude 12 articles for which the full text was not available and to include 25 publications describing 25 randomized controlled trials (RCTs) (Figure 1) [7]. Twenty-five RCTs contributed to the quantitative analyses. In addition, 14 articles not included in the analyses were obtained from manual searches to contrast results from other authors.




Figure 1: Flow Chart diagram.

### Characteristics of the studies included

Twenty-five randomized clinical trials (RCTs), published between 1995 and 2025 were included, with a total of 684 patients evaluated. In Table 1 we present characteristics of the 25 studies included in the review [1-3, 8-29].

The sample size per study ranged from 9 to 72 participants, the largest study being that of Jung *et al.* [19], while the smallest was by Majzoub *et al.* [24]. Follow-up time ranged from 4 to 168 months, although most studies established short- or medium-term follow-up ( $\leq 12$  months).

**Table 1:** Characteristics of the 25 studies included in the review. T of S: Type of study. RCT: Randomized clinical trial. d-PtFE: Dense polytetrafluoroethylene. e-PtFE: Expanded polytetrafluoroethylene. Ti mesh: Titanium mesh. PBL-V: Vertical infraosseous defect. MGCSH: Medical grade calcium sulfate hemihydrate.

Study (author, year)	Type of membrane	T of S, [N]	Localization	Follow-up (months)	Bone graft	Success rate (%)	Complications (%)	Bone formation (mm)	Risk of bias
Cucchi <i>et al.</i> 2017 (1)	d-PtFE vs. titanium mesh covered with Cross-linked collagen	RCT [1]	Atrophic posterior mandible	12 months	50% autogenous and 50% allograft	d-PtFE: 100% Ti mesh: 100%	d-PtFE: 5% surgical-15% complications vs. Ti mesh: 15.28% surgical-21.9% complications	d-PtFE: 4.2±1.1mm vs. Ti mesh: 4.1±1.1mm	Low
Eickholz <i>et al.</i> 2007 (2)	e-PtFE vs. Polyglactin 910, polylactide-tributylcitrate	RCT [8]	Infrabony defect, maxilla and mandible	60±3 months	No	94%	e-PtFE: 0% vs. Polidioxanone: 2%	PBL-V gain: 1.78±2.67mm Density: +0.16±0.33mm	Moderate
Van der Zee <i>et al.</i> 2004 (9)	e-PtFE vs. Polylactide/polyglycolide	RCT [9]	Maxilla bone defect	12 months	Xenograft, blood cloth only	100%	25% recession	-0.34mm	Moderate
Cucchi <i>et al.</i> 2019 (3)	Ti-PtFE vs. Collagen plus Ti-mesh	RCT [3]	Posterior mandible	9 months	50% autogenous, 50% allograft	100%	7.5% Ti-PtFE vs. 7.5% Collagen plus Ti-mesh	B.Pi. Ti-PtFE: 7.8±1.9mm vs. Collagen plus Ti-mesh: 7.4±2.3mm	Low
Cucchi <i>et al.</i> 2019 (10)	d-PtFE vs. Collagen Ti-mesh	RCT [10]	Posterior mandible	9 months	50% autogenous, 50% allograft	100%	7.5%	d-PtFE: 4.2±1.1mm vs. Ti mesh: 4.1±1.1mm	Low
Kim <i>et al.</i> 2002 (11)	e-PtFE vs. Polyglactin 910	RCT [11]	Infrabony defect	60±3 months	No	100%	e-PtFE: 2.5%	e-PtFE: 1.5mm vs. Polyglactin 910: 2.1mm	High
Eickholz <i>et al.</i> 2006 (8)	e-PtFE vs. Polyglactin 910	RCT [2]	Class II furcation	120±6 months	No	89%	e-PtFE: 11% vs. Polyglactin 910: 11%	e-PtFE: 1.1±1.3mm vs. Polyglactin 910: 1.7±1.4mm	High
Carpio <i>et al.</i> 2000 (12)	e-PtFE vs. Collagen	RCT [12]	Ossous defects surrounding dental implants	6 months	Xenograft 50% Autograft 50%	e-PtFE: 83.3% Collagen: 78.3%	e-PtFE: dehiscence 4.1% and exposure 12.5% Collagen: 8.7% exposure	e-PtFE: 2.26±0.66mm vs. Collagen: 2.65±0.61mm	Moderate
Silvestri <i>et al.</i> 2000 (13)	e-PtFE vs. enamel matrix derivative vs. Widman modified flap	RCT [13]	Infrabony defect	12 months	No	100%	e-PtFE: 70% exposure	e-PtFE: 4.8±2.1 mm vs. EMD: 4.5±1.6mm vs. WMF: 1.2±1.0mm	Moderate
Couri <i>et al.</i> 2002 (14)	e-PtFE vs. barrier of medical grade calcium sulfate hemihydrate [MGCSH]	RCT [14]	Class II furcation	12 months	Deminerarized freeze-dried bone allograft [DFDBA]	100%	e-PtFE: 15% infection	e-PtFE: 2.54±1.56mm vs. MGCSH: 1.38±1.12mm (horizontal fill)	Low
Friedmann <i>et al.</i> 2003 (15)	e-PtFE vs. Collagen	RCT [15]	Infrabony defect	7 months	Xenograft	100%	e-PtFE: 71% vs. Collagen: 64% exposure	e-PtFE: 3.9%±1.5% vs. Collagen: 4.2%±1.8%	Low
Khoury <i>et al.</i> 2001 (16)	e-PtFE vs. Collagen	RCT [16]	Ossous defects surrounding dental implants	36 months	Autogenous	100%	e-PtFE: 60% dehiscence, fistula, exposure, sequestration vs. Collagen: 55.6%	e-PtFE: 2.8±3.1mm vs. Collagen: 1.9±3.2mm	High
Naenni <i>et al.</i> 2017 (17)	e-PtFE vs. Collagen	RCT [17]	Buccofenestrated defect	6 months	Xenograft	100%	e-PtFE: 14% dehiscence vs. Collagen: 30% dehiscence	e-PtFE: 2.14±2.06mm vs. Collagen: 3.41±2.33mm	Moderate
Naenni <i>et al.</i> 2021 (18)	e-PtFE vs. Collagen	RCT [18]	Dehiscence or fenestration defect	60 months	Xenograft	95%	Collagen: 4%	e-PtFE: -1.08mm Collagen: -1.6mm	Moderate
Jung <i>et al.</i> 2013 (19)	e-PtFE vs. Collagen	RCT [19]	Infrabony defect	144-168 months	Xenograft	e-PtFE: 92.6% Collagen: 91.9%	e-PtFE>Collagen	e-PtFE: 2.4mm vs. Collagen: 3.36mm	Low
Mandarino <i>et al.</i> 2018 (20)	d-PtFE vs. cloth	RCT [20]	Extraction sockets	4 months	No	100%	0%	d-PtFE: 4.30±1.20mm Cloth: 2.50±2.20mm	High

**Table 1:** Characteristics of the 25 studies included in the review. T of S: Type of study. RCT: Randomized clinical trial. d-PTFE: Dense polytetrafluoroethylene. e-PTFE: Expanded polytetrafluoroethylene. Ti mesh: Titanium mesh. PBL-V: Vertical infraosseous defect. MGCSh: Medical grade calcium sulfate hemihydrate. (Cont.)

Author et al. (Year)	Comparison	Study Design	Sites for implant placement	Duration	Autogenous	Success Rate (%)	Complications	Outcome
Vaibhav et al. 2021 (21)	e-PTFE vs. Collagen	RCT [21]	Post-extraction alveolar bone defects	24 months	Autogenous	100%	0%	e-PTFE: 2.43±0.128mm vs. Collagen: 2.42±0.131mm
Laongo et al. 2022 (22)	d-PTFE vs. cloth	RCT [22]	Post-extraction alveolar bone defects	30 months	Xenograft	100%	0%	d-PTFE: 16.81%±9.61% vs. Cloth: 35.16%±12.36%
Chen et al. 2004 (23)	e-PTFE vs. Poly(lactide/polyglycolide) vs. Cloth vs. Bone graft	RCT [23]	Maxillary Extraction sockets	6 months	Autogenous	96.8%	9.7% infection, abscess, exposure	e-PTFE: 1.8±0.2mm vs. Poly(lactide/polyglycolide): 1.8±0.3mm vs. Bone graft: 1.6±0.2mm vs. Cloth: 1.5±0.3
Mazjoub et al. 1999 (24)	e-PTFE	RCT [24]	Infabony defect	8 months	No	100%	Control: 22% Fenestration, infection	e-PTFE: 3.1±1.1mm
Dahlin et al. 2010 (25)	e-PTFE vs. Collagen	RCT [25]	Infabony defect anterior maxilla	6 months	Xenograft 80% autogenous 20%	97.5%	5% exposition	MBL: -3.51 to -2.38mm
Antoun et al. 2001 (26)	e-PTFE vs. Autogenous graft	RCT [26]	Infabony defect	6 months	Autogenous	100%	e-PTFE: 8.3% exposition	e-PTFE: 3.7mm vs. Graft: 2.9mm
Merli et al. 2014 (27)	e-PTFE vs. Collagen	RCT [27]	Infabony defect	72 months	Autogenous	100%	0%	e-PTFE: -0.49mm vs. Collagen: -0.58mm
Scott et al. 1997 (28)	e-PTFE vs. Laminar bone	RCT [28]	Class II furcation	6 months	Allograft	100%	e-PTFE: significant exposure (up to 1.8mm) weeks 3-5	e-PTFE Vertical: 1.0-1.2mm vs. Horizontal: 2.0-2.2mm
Strauss et al. 2025 (29)	e-PTFE vs. Collagen	RCT	Anterior region	6 months	DeminerIALIZED bovine bone mineral (DBBM)	e-PTFE: 84.6% Collagen: 66.7%	e-PTFE: 15.4% dehiscence vs. Collagen: 33.3% dehiscence	e-PTFE: -0.1mm (p=0.017) vs. Collagen: -0.8mm

The most common anatomic locations were infraosseous and furcation class II defects, followed by postextraction and peri-implant defects. Most of the procedures were performed in the posterior mandibular region and in the anterior maxilla.

Regarding the type of intervention, the studies mainly compared non-resorbable membranes (especially e-PTFE and d-PTFE) with resorbable membranes (collagen, polyglactin 910, polylactide/polyglycolide). In addition, some studies evaluated variants with titanium mesh or textile membranes. Of all the studies, 19 used bone grafts (autogenous, xenografts, allogeneic or combinations), while 6 did not use any additional biomaterial.

In relation to bone formation, the results were variable. For example, Cucchi *et al.* [3] reported a vertical gain of 7.8±1.9mm with Ti-PTFE membranes, while 7.4±2.3mm was obtained with collagen and titanium mesh. Silvestri *et al.* [13] recorded a gain of 4.8±2.1mm with e-PTFE. In contrast, Van der Zee *et al.* [9] observed a volume loss of -0.34mm, which highlights the influence of the type of membrane, the defect treated and the surgical protocol.

Regarding complications, these were frequent with non-resorbable membranes. Membrane exposure was the most reported, present in at least 12 studies, with rates reaching up to 71% in the study by Friedmann *et al.* and 70% in the study by Silvestri *et al.* [13]. Other common complications included dehiscence, infection and gingival recession. In contrast, studies such as those by Mandarino *et al.* [20] Vaibhav *et al.* [21] and Merli *et al.* [27] reported no relevant adverse events.

Most studies reported success rates above 90%, especially in the groups treated with resorbable membranes. However, the definition of “success” was variable among studies, including clinical, radiographic or histologic criteria.

#### Risk of bias in the studies and certainty of evidence

Of the 25 studies included in the review, 11 were at low risk of bias, whereas 6 presented moderate risk and 8 were classified as high risk (Table 2).

The main sources of bias were associated with methodological limitations related to lack of blinding, small sample sizes, and lack of long-term follow-up. These shortcomings compromise the internal validity of the studies and, consequently, influence the overall certainty of the evidence.

The quality of the evidence was degraded mainly by these limitations in the design and by the imprecision of the results.

#### Quantitative data synthesis

A meta-analysis was performed with the studies that provided comparable data between membranes. The following parameters were studied: Bone formation, success rate and complications.

In the comparison between e-PTFE and collagen membranes, no statistically significant differences were observed in terms of Bone formation: The mean dif-

**Table 2:** Risk of bias in the articles included in the systematic review. +: Low. Un: Unclear. -: High.

Study	Random Sequence Generation	Allocation Concealment	Blinding of Participants and Researchers	Incomplete Outcome Data	Selective Reporting	Other Bias	General Risk of Bias
Cucchi <i>et al.</i> 2017 (1)	+	+	+	+	+	+	+
Eickholz <i>et al.</i> 2007 (2)	-	Un	Un	-	Un	Un	Un
Van der Zee <i>et al.</i> 2004 (9)	+	Un	Un	-	Un	Un	Un
Cucchi <i>et al.</i> 2019 (3)	Un	+	+	+	Un	+	+
Cucchi <i>et al.</i> 2019 (10)	+	+	Un	+	Un	Un	+
Kim <i>et al.</i> 2002 (11)	-	Un	Un	-	Un	-	-
Eickholz <i>et al.</i> 2006 (8)	Un	-	Un	-	Un	Un	-
Carpio <i>et al.</i> 2000 (12)	Un	+	+	Un	-	Un	Un
Silvestri <i>et al.</i> 2000 (13)	+	Un	-	+	+	Un	Un
Couri <i>et al.</i> 2002 (14)	+	+	+	Un	+	Un	+
Friedmann <i>et al.</i> 2003 (15)	Un	+	Un	+	Un	+	+
Khoury <i>et al.</i> 2001 (16)	-	Un	Un	-	Un	Un	-
Naenni <i>et al.</i> 2017 (17)	Un	+	Un	+	+	Un	Un
Naenni <i>et al.</i> 2021 (18)	Un	+	Un	+	+	Un	Un
Jung <i>et al.</i> 2013 (19)	+	+	Un	+	+	Un	+
Mandarino <i>et al.</i> 2018 (20)	Un	Un	Un	-	Un	Un	-
Vaibhav <i>et al.</i> 2021 (21)	+	+	Un	+	+	+	+
Luongo <i>et al.</i> 2022 (22)	Un	-	+	+	Un	Un	-
Chen <i>et al.</i> 2004 (23)	+	+	+	+	+	+	+
Mazjoub <i>et al.</i> 1999 (24)	-	Un	Un	-	Un	Un	-
Dahlin <i>et al.</i> 2010 (25)	+	+	Un	+	+	+	+
Antoun <i>et al.</i> 2001 (26)	Un	-	Un	-	Un	Un	-
Merli <i>et al.</i> 2014 (27)	+	+	+	+	+	+	+
Scott <i>et al.</i> 1997 (28)	-	Un	Un	-	Un	Un	-
Strauss <i>et al.</i> 2025 (29)	Un	+	Un	+	+	+	+

ference was -0.09mm; with a 95% confidence interval (CI): -0.41 to 0.22;  $P=0.56$ , although the heterogeneity between studies was high ( $I^2=49\%$ ) (Figure 2A).

In the success rate: The risk ratio was 1.00 with a 95% CI of 0.95 to 1.06;  $P=0.89$ , with zero heterogeneity between studies ( $I^2=0\%$ ) (Figure 2B). And the complications: The “risk ratio” was 1.01 with 95% CI: 0.69 to 1.48;  $P=0.98$ , with null heterogeneity between studies ( $I^2=0\%$ ) (Figure 2C).

When comparing e-PTFE with polylactin 910 membranes, no statistically significant differences were found: Success rate: The risk ratio was 1.03 with a 95% CI of 0.84 to 1.26;  $P=0.76$ , with no heterogeneity between studies ( $I^2=0\%$ ) (Figure 3A). And the complications: The “risk ratio” was 1.00 with 95% CI: 0.02 to 45.50;  $P=1.00$ , although heterogeneity among studies was high ( $I^2=72\%$ ) (Figure 3B). And the the comparison of e-PTFE with polylactide/polylactin 910 no statistically significant differences were found: Success rate: The risk ratio was 0.98 with a 95% CI of 0.87 to 1.10;  $P=0.70$ , with zero heterogeneity between studies ( $I^2=0\%$ ) (Figure 3C).

## Discussion




This systematic review compared the clinical efficacy and complications associated with the use of resorbable and non-resorbable membranes in guided bone regeneration (GBR) procedures. Overall, both showed satisfactory results in bone formation and graft stability, although with different complication profiles.

### Clinical efficacy: Bone formation and graft stability



Regarding treatment efficacy, evaluated by bone formation and graft stability, no significant differences were found between resorbable and non-resorbable membranes in studies with follow-up of less than 24 months [2]. However, the quality of regenerated bone and its long-term stability remain critical aspects for success [3]. Studies with Ti-PTFE membranes or titanium meshes showed similar proportions of new bone, residual bio-material and soft tissue. For example, with a 50:50 mixture of autologous bone and allograft, 39.7% new bone was obtained with Ti-PTFE and 42.1% with collagen membrane and titanium mesh [3]. Urban *et al.* [30] reported similar results: 36.6% new bone, 16.6% residual material and 46.8% soft tissue when Ti-PTFE was used with autogenous bone and DBBM [3].

The optimal healing time continues to be debated, but an average of 9 months is recommended; 6 months is acceptable for horizontal and 9 months for vertical augmentations. Some studies have even reported good results in vertical augmentations after 6 months [3]. In the study by Cucchi *et al.* [3], the titanium mesh group showed more bone tissue and less soft tissue than the Ti-PTFE group, possibly due to better revascularization associated with resorbable membranes, as opposed to the greater rigidity of PTFE.

Regarding long-term stability, Kim *et al.* [11] observed that vertical gain with polyglactin 910 remained relatively stable, with a mean loss of only 1.0mm between 6 and 60 months. Similar results were obtained with ePT-




**Figure 2:** (A) Meta-analysis of bone formation comparing e-PTFE membranes versus collagen membranes. (B) Meta-analysis of success rate comparing e-PTFE membranes versus collagen membranes. (C) Meta-analysis of complications comparing e-PTFE membranes versus collagen membranes.



**Footnotes**

<sup>a</sup>CI calculated by Wald-type method.

<sup>b</sup>Tau<sup>2</sup> calculated by Restricted Maximum-Likelihood method.



**Figure 3:** (A) Meta-analysis of success rate comparing e-PTFE membranes versus pologlactin 910 membranes. (B) Meta-analysis of complications comparing e-PTFE membranes versus pologlactin 910 membranes. (C) Meta-analysis of success rate comparing e-PTFE membranes versus poly lactide/pologlactin 910 membranes.

FE membranes: Losses of 0.9mm between 12 and 24 months [17], and 1.2mm after ROG versus 1.3mm after conventional surgery [18]. These losses were mainly related to smoking or low adherence to maintenance [11]. Kim *et al.* [11] also studied the IL-1 $\beta$  polymorphism, linked to an increased inflammatory response. In the study by Sanctis *et al.* [31], 75% of patients were genotype-positive, compared with the expected 33%. Only two negative patients showed significant loss, which reinforces the role of this polymorphism as a risk factor. In simultaneous ROG and implant installation procedures, Naenni *et al.* [17] documented a significant reduction of the bone defect (2.14-3.41mm) from ini-

tial surgery to reentry. Although both groups lost horizontal thickness, it was less in the group without resorbable membrane (N-RES), suggesting that collagen membranes may collapse even with bone support. At 5 years, bone changes were minimal, but more stable in the N-RES group (-0.24mm vs. -0.28mm in RES), possibly because of the greater barrier capacity of ePTFE [18].

In the long term, Jung *et al.* [19] reported a survival rate of 93% at 12.5 years, higher than that of other studies reporting 89.3% at 10 years and 82.9% at 16 years, demonstrating the potential for ROG stability over time. -Complications according to membrane type

The choice of membrane type implies different complication profiles. Non-resorbable membranes, such as ePTFE and titanium meshes, have a higher rate of exposure, which may compromise bone regeneration [1]. These exposures, both early and late, are the main cause of procedure failure and can lead to infections, abscesses or total graft loss, even without visible exposure [1]. Exposure rates range from 0-45% for PTFE membranes and 12-50% for titanium meshes, according to Strauss *et al.* Simion *et al.* and Rocuzzo *et al.* [29, 32, 33]. In early exposures (first 4 weeks), a direct correlation was observed between the exposed area and bone loss, with a deficit of 16.3% per cm<sup>2</sup> exposed. Paresthesias were also reported (one with d-PTFE, three with Ti mesh), linked to closures under tension or surgical difficulty [1]. Collagen membranes had more implant exposures, although less dehiscence than ePTFE during the first six months. Similar results were obtained by Zitzmann *et al.* [34]. Fixation with polylactic acid pins improved healing (63.6% vs. 28.6% in unfixed membranes), reducing postoperative micromovement [9].

Another disadvantage of non-resorbable membranes is the need for a second surgery for their removal, which can induce gingival recession and flap necrosis. In addition, they require intensive surveillance in case of exposure or suppuration, since spontaneous healing is limited [23, 24]. Strietzel [35] reported exposure rates of up to 50% with ePTFE membranes. In contrast, biodegradable membranes favored a more predictable healing without the need for removal for Simion *et al.* [36]. In combination with enamel matrix derivatives (DBBM), collagen membranes achieved defect resolution rates of 85-96%, higher than those observed with non-resorbable membranes, which had greater exposure and less bone fill [10, 37]. Despite a higher number of dehiscences with collagen (30% vs. 14%), thickness loss was lower in the N-RES group, indicating greater dimensional stability. The collapsibility of resorbable membranes remains a limitation, even with support [10].

Although ePTFE membranes have proven clinical success, their vulnerability to bacterial colonization due to their macroporosity compromises outcomes [10]. Survival rates with these membranes vary between 79.4% and 100%, but they present greater bone loss associated with soft tissue complications. In contrast, collagen membranes achieved a rate of 95.4% in the study by Zitzmann *et al.* [38].

After the date our search was completed, a new trial was published by Hindryckx *et al.* [39] comparing dPTFE and collagen membranes in lateral bone augmentations in the maxillary anterior region. Although both groups showed similar results in terms of bone gain at 9 months, the group treated with dPTFE had a higher rate of infections (33%,  $P=0.019$ ), which reinforces the evidence on the complications associated with the use of non-resorbable membranes.

In immediate implants, exposures were observed in areas with connective tissue grafts (9.7%), with abscesses in 3.2% and reduction of bone volume in exposed areas. Only one out of four areas showed unsatisfactory regeneration, suggesting that resorbable membranes might offer better protection against bacterial migration in case of exposure [23].

Finally, although with small samples, the data indicate that smokers have a worse response to regenerative therapy, regardless of the type of membrane. Tonetti *et al.* [40] observed lower long-term clinical gains in smokers with ePTFE membranes, despite similar bone regeneration.

The findings of the meta-analysis indicate that there are no statistically significant differences between collagen and e-PTFE membranes in terms of bone formation (mean difference: -0.09mm; 95% CI: -0.41 to 0.22;  $P=0.56$ ), success rate (RR=1.00; 95% CI: 0.95 to 1.06;  $P=0.89$ ) and complications (RR=1.01; 95% CI: 0.69 to 1.48;  $P=0.98$ ), with null heterogeneity for the last two parameters ( $I^2=0\%$ ).

Similarly, when comparing e-PTFE with polyglactin 910, no statistically significant differences were found in the success rate (RR=1.03; 95% CI: 0.84 to 1.26;  $P=0.76$ ;  $I^2=0\%$ ) or in the occurrence of complications (RR=1.00 with 95% CI: 0.02 to 45.50;  $P=1.00$ ), although it showed high heterogeneity ( $I^2=72\%$ ), suggesting some variability between studies. Finally, in the comparison between e-PTFE and polylactide/polyglycolide, no significant differences were found in the success rate (RR=0.98; 95% CI: 0.87 to 1.10;  $P=0.70$ ;  $I^2=0\%$ ).

An important limitation of this review is the methodological heterogeneity among the included studies, both in sample size and in the type and location of the bone defects treated. Similarly, the diversity in the biomaterials used, the follow-up time and the variability in the surgical techniques employed make direct comparison of the results difficult. The scarcity of clinical trials with long-term follow-up also represents a disadvantage in establishing definitive conclusions on the stability of the results over time. In addition, study selection was primarily conducted by a single reviewer, with consultation in cases of uncertainty, which may have introduced a risk of selection bias. Sensitivity and subgroup analyses were limited by the heterogeneity of study designs, membrane types, outcome measures, and the relatively small number of comparable studies available for quantitative synthesis. Nevertheless, the certainty of evidence was assessed at the outcome level using the GRADE approach, providing a structured evaluation of the confidence in the estimated effects.

Future research should focus on randomized clinical trials with a larger sample size and long-term follow-up to compare the efficacy and complications associated with the different types of membranes. It would also be opportune to delve into the impact of systemic and genetic factors, such as IL-1 $\beta$  polymorphism on the success of bone regeneration.

In conclusion, both resorbable and non-resorbable membranes are effective and achieve predictable bone regeneration, with high success rates in most studies. Since there are no statistically significant differences, the choice of membrane type should be individualized according to the defect, the type of intervention and the patient's clinical history. This is due to the differences in the complication profile, especially the higher frequency of exposures and infections with non-resorbable membranes, even though they offer greater dimensional stability and the need for a second surgery for their removal. In contrast, resorbable membranes have a lower rate of complications.

#### Acknowledgment

Declared none.

#### Institutional Review Board Statement

Not applicable. This study is a systematic review of published data. This review was registered in PROSPERO (registration number: CRD420251085754). The review protocol is available at: <https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085754>. No amendments to the registered protocol were made.

#### Author Contributions

Conceptualization: D.S.C., S.E.-M. and J.L.-L. Methodology: D.S.C., S.E.-M. and J.L.-L. Software: S.E.-M. Validation: J.L.-L. and B.G.N. Formal analysis: S.E.-M. Investigation: D.S.C., S.E.-M. and B.G.N. Resources: D.S.C., S.E.-M., J.L.-L., H.O.M. and B.G.N. Data curation: D.S.C. and S.E.-M. Writing-original draft preparation: D.S.C., H.O.M. Writing-review and editing: S.E.-M., H.O.M. and J.L.-L. Visualization: J.L.-L. Supervision: J.L.-L. Project administration: J.L.-L. and S.E.-M. Funding acquisition: D.S.C., S.E.-M., J.L.-L. and B.G.N. All authors have read and agreed to the published version of the manuscript.

#### Funding

This research did not have any funding sources.

#### Conflicts of Interest

The authors declare no conflicts of interest, financial or otherwise.

#### References

- Cucchi A, Vignudelli E, Napolitano A, Marchetti C, Corinaldesi G. Evaluation of complication rates and vertical bone gain after guided bone regeneration with non-resorbable membranes versus titanium meshes and resorbable membranes. A randomized clinical trial. *Clin Implant Dent Relat Res.* 2017; 19(5):821-832.
- Eickholz P, Pretzl B, Holle R, Kim T. Long-Term Results of Guided Tissue Regeneration Therapy with Non-Resorbable and Bioabsorbable Barriers. III. Class II Furcations After 10 Years. *J Periodontol.* 2006; 77(1):88-94.
- Cucchi A, Sartori M, Parrilli A, Aldini NN, Vignudelli E, Corinaldesi G. Histological and histomorphometric analysis of bone tissue after guided bone regeneration with non-resorbable membranes vs resorbable membranes and titanium mesh. *Clin Implant Dent Relat Res.* 2019; 21(4):693-701.
- Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, *et al.* The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. *Ann Intern Med.* 2015; 162(11):777-784.
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, *et al.* RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ.* 2019;366: 14898.
- Puhan MA, SHJ, MMH, LT, BPR, SJA, KAG, GGH, & GWGroup. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ.* 2015;350:h3326.

- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, *et al.* The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ.* 2021;372: n71.
- Eickholz P, Krigar D, Kim T, Reitmeir P, Rawlinson A. Stability of Clinical and Radiographic Results After Guided Tissue Regeneration in Infrabony Defects. *J Periodontol.* 2007;78(1):37-46.
- Van Der Zee E, Oosterveld P, Van Waas MAJ. Effect of GBR and fixture installation on gingiva and bone levels at adjacent teeth. *Clin Oral Implants Res.* 2004;15(1):62-65.
- Cucchi A, Sartori M, Aldini N, Vignudelli E, Corinaldesi G. A Proposal of Pseudo-periosteum Classification After GBR by Means of Titanium-Reinforced d-PTFE Membranes or Titanium Meshes Plus Cross-Linked Collagen Membranes. *Int J Periodontics Restorative Dent.* 2019;39(4): e157-165.
- Kim T, Holle R, Hausmann E, Eickholz P. Long-Term Results of Guided Tissue Regeneration Therapy with Non-Resorbable and Bioabsorbable Barriers. II. A Case Series of Infrabony Defects. *J Periodontol.* 2002; 73(4):450-459.
- Carpio L, Loza J, Lynch S, Genco R. Guided Bone Regeneration Around Endosseous Implants with Anorganic Bovine Bone Mineral. A Randomized Controlled Trial Comparing Bioabsorbable Versus Non-Resorbable Barriers. *J Periodontol.* 2000; 71(11):1743-17449.
- Silvestri M, Ricci G, Rasperini G, Sartori S, Cattaneo V. Comparison of treatments of infrabony defects with Enamel Matrix Derivative, Guided Tissue Regeneration with a nonresorbable membrane and Widman Modified Flap: A pilot study. *J Clin Periodontol.* 2000; 27(8):603-610.
- Couri CJ, Maze GI, Hinkson DW, Collins BH, Dawson D V. Medical Grade Calcium Sulfate Hemihydrate Versus Expanded Polytetrafluoroethylene in the Treatment of Mandibular Class II Furcations. *J Periodontol.* 2002; 73(11):1352-1359.
- Friedmann A, Strietzel FP, Maretzki B, Pitaru S, Bernimoulin JP. Histological assessment of augmented jawbone utilizing a new collagen barrier membrane compared to a standard barrier membrane to protect a granular bone substitute material: A randomized clinical trial. *Clin Oral Implants Res.* 2002; 13(16):587-594.
- Khoury F, Buchmann R. Surgical Therapy of Peri-Implant Disease: A 3-Year Follow-Up Study of Cases Treated With 3 Different Techniques of Bone Regeneration. *J Periodontol.* 2001; 72(11):1498-508.
- Naenni N, Schneider D, Jung RE, Hüsler J, Hämmerle CHF, Thoma DS. Randomized clinical study assessing two membranes for guided bone regeneration of peri-implant bone defects: Clinical and histological outcomes at 6 months. *Clin Oral Implants Res.* 2017; 28(10):1309-1317.
- Naenni N, Stucki L, Hüsler J, Schneider D, Hämmerle CHF, Jung RE, *et al.* Implants sites with concomitant bone regeneration using a resorbable or non-resorbable membrane result in stable marginal bone levels and similar profilometric outcomes over 5 years. *Clin Oral Implants Res.* 2021; 32(8):893-904.
- Jung RE, Fenner N, Hämmerle CHF, Zitzmann NU. Long-term outcome of implants placed with guided bone regeneration (GBR) using resorbable and non-resorbable membranes after 12-14 years. *Clin Oral Implants Res.* 2013; 24(10):1065-1073.
- Mandarino D, Luz D, Moraschini V, Rodrigues DM, Barboza ESP. Alveolar ridge preservation using a non-resorbable membrane: Randomized clinical trial with biomolecular analysis. *Int J Oral Maxillofac Surg.* 2018; 47(11):1465-1473.
- Vaibhav V, Sinha A, Bolisetty D, Verma A, Kumar K, Singh S. Osseointegration of dental implants in ridges with insufficient bones using different membranes for guided bone regeneration. *J Pharm Bioallied Sci.* 2021;13(Suppl 1): S225-228.
- Luongo R, Tallarico M, Canciani E, Graziano D, Dellavia C, Gargari M, *et al.* Histomorphometry of Bone after Intentionally Exposed Non-Resorbable d-PTFE Membrane or Guided Bone Regeneration for the Treatment of Post-Extractive Alveolar Bone Defects with Implant-Supported Restorations: A Pilot Randomized Controlled Trial. *Materials.* 2021; 15(17):5838.
- Chen ST, Darby IB, Adams GG, Reynolds EC. A prospective clinical study of bone augmentation techniques at immediate implants. *Clin Oral Implants Res.* 2005; 16(2):176-184.

24. Majzoub Z, Cordioli G, Aramouni PK, Vigolo P, Piattelli A. Guided bone regeneration using demineralized laminar bone sheets versus GTAM membranes in the treatment of implant-associated defects: A clinical and histological study. *Clin Oral Implants Res.* 1999; 10(5):406-414.
25. Dahlin C, Simion M, Hatano N. Long-Term Follow-Up on Soft and Hard Tissue Levels Following Guided Bone Regeneration Treatment in Combination with a Xenogeneic Filling Material: A 5-Year Prospective Clinical Study. *Clin Implant Dent Relat Res.* 2010; 12(4):263-270.
26. Antoun H, Sitbon JM, Martinez H, Missika P. A prospective randomized study comparing two techniques of bone augmentation: Onlay graft alone or associated with a membrane. *Clin Oral Implants Res.* 2001; 12(6):632-639.
27. Merli M, Moscatelli M, Mariotti G, Rotundo R, Bernardelli F, Nieri M. Bone Level Variation After Vertical Ridge Augmentation: Resorbable Barriers Versus Titanium-Reinforced Barriers. A 6-Year Double-Blind Randomized Clinical Trial. *Int J Oral Maxillofac Implants.* 2014; 29(4):905-913.
28. Scott TA, Towle HJ, Assad DA, Nicoll BK. Comparison of Bioabsorbable Laminar Bone Membrane and Non-Resorbable ePTFE Membrane in Mandibular Furcations. *J Periodontol.* 1997; 68(7):679-686.
29. Strauss FJ, Schneider D, Jung RE, Kraus R, Thoma DS, Naenni N. Hard and soft tissue contour changes following simultaneous guided bone regeneration at single peri-implant dehiscence defects using either resorbable or non-resorbable membranes: A 6-month secondary analysis of a randomized controlled trial. *Clin Oral Investig.* 2025; 29(5):231.
30. Urban IA, Lozada JL, Jovanovic SA, Nagursky H, Nagy K. Vertical ridge augmentation with titanium-reinforced, dense-PTFE membranes and a combination of particulated autogenous bone and anorganic bovine bone-derived mineral: A prospective case series in 19 patients. *Int J Oral Maxillofac Implants.* 2014; 29(1):185-193.
31. De Sanctis M, Zucchelli G. Interleukin-1 gene polymorphisms and long-term stability following guided tissue regeneration therapy. *J Periodontol.* 2000; 71(4):606-613.
32. Simion M, Fontana F, Rasperini G, Maiorana C. Long-term evaluation of osseointegrated implants placed *in sites* augmented with sinus floor elevation associated with vertical ridge augmentation: A retrospective study of 38 consecutive implants with 1- to 7-year follow-up. *Int J Periodontics Restorative Dent.* 2004; 24(3):208-221.
33. Rocuzzo M, Ramieri G, Bunino M, Berrone S. Autogenous bone graft alone or associated with titanium mesh for vertical alveolar ridge augmentation: A controlled clinical trial. *Clin Oral Implants Res.* 2007; 18(3):286-294.
34. Zitzmann NU, Schärer P, Marinello CP. Long-term results of implants treated with guided bone regeneration: A 5-year prospective study. *Int J Oral Maxillofac Implants.* 2001; 16(3):355-366.
35. Strietzel FP. [Risks and complications of membrane-guided bone regeneration. Retrospective analysis]. *Mund Kiefer Gesichtschir.* 2001; 5(1):28-32.
36. Simion M, Misitano U, Gionso L, Salvato A. Treatment of dehiscences and fenestrations around dental implants using resorbable and nonresorbable membranes associated with bone autografts: A comparative clinical study. *Int J Oral Maxillofac Implants.* 1997; 12(2):159-167.
37. Poli PP, Giboli L, Manfredini M, Khijmatgar S, Souza FÁ, Maiorana C. Horizontal Bone Augmentation with Natural Collagen Porcine Pericardium Membranes: A Prospective Cohort Study. *Medicina (Kaunas).* 2025; 61(10):1814.
38. Zitzmann NU, Naef R, Schärer P. Resorbable versus nonresorbable membranes in combination with Bio-Oss for guided bone regeneration. *Int J Oral Maxillofac Implants.* 1997; 12(6):844-852.
39. Hindryckx M, De Bruyckere T, De Buyser S, Seyssens L, Shitino R, Younes F, *et al.* A Multi-Centre Randomised Controlled Trial Comparing dPTFE Membrane to Collagen Membrane in Lateral Bone Augmentation at Single Sites in the Anterior Maxilla: 1-Year Results. *J Clin Periodontol.* 2025; 52(8):1136-1146.
40. Tonetti MS, Pini-Prato G, Cortellini P. Effect of cigarette smoking on periodontal healing following GTR in infrabony defects. A preliminary retrospective study. *J Clin Periodontol.* 1995; 22(3):229-234.